
Orchard Therapeutics is a biotechnology business based in the US. Orchard Therapeutics shares (ORTX) are listed on the NASDAQ and all prices are listed in US Dollars. Orchard Therapeutics employs 259 staff and has a trailing 12-month revenue of around $16.2 million.
How to buy Orchard Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ORTX. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Orchard Therapeutics stock price (NASDAQ: ORTX)
Use our graph to track the performance of ORTX stocks over time.Orchard Therapeutics shares at a glance
Latest market close | $0.57 |
---|---|
52-week range | $0.36 - $1.23 |
50-day moving average | $0.48 |
200-day moving average | $0.52 |
Wall St. target price | $3.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.21 |
Buy Orchard Therapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Orchard Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Orchard Therapeutics price performance over time
Historical closes compared with the close of $0.57 from 2023-01-27
1 week (2023-01-23) | -9.52% |
---|---|
1 month (2022-12-30) | 54.05% |
3 months (2022-10-28) | 26.67% |
6 months (2022-07-29) | 7.55% |
1 year (2022-01-28) | -35.23% |
---|---|
2 years (2021-01-29) | -90.09% |
3 years (2020-01-30) | 12.92 |
5 years (2018-01-26) | N/A |
Orchard Therapeutics financials
Revenue TTM | $16.2 million |
---|---|
Gross profit TTM | $-85,528,000 |
Return on assets TTM | -27.58% |
Return on equity TTM | -98.15% |
Profit margin | 0% |
Book value | $0.98 |
Market capitalisation | $73.2 million |
TTM: trailing 12 months
Orchard Therapeutics share dividends
We're not expecting Orchard Therapeutics to pay a dividend over the next 12 months.
Orchard Therapeutics share price volatility
Over the last 12 months, Orchard Therapeutics's shares have ranged in value from as little as $0.36 up to $1.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orchard Therapeutics's is 0.6891. This would suggest that Orchard Therapeutics's shares are less volatile than average (for this exchange).
Orchard Therapeutics overview
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N. V.
Orchard Therapeutics in the news
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Frequently asked questions
What percentage of Orchard Therapeutics is owned by insiders or institutions?Currently 6.052% of Orchard Therapeutics shares are held by insiders and 44.34% by institutions. How many people work for Orchard Therapeutics?
Latest data suggests 259 work at Orchard Therapeutics. When does the fiscal year end for Orchard Therapeutics?
Orchard Therapeutics's fiscal year ends in December. Where is Orchard Therapeutics based?
Orchard Therapeutics's address is: 108 Cannon Street, London, United Kingdom, EC4N 6EU What is Orchard Therapeutics's ISIN number?
Orchard Therapeutics's international securities identification number is: US68570P1012 What is Orchard Therapeutics's CUSIP number?
Orchard Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68570P101
More guides on Finder
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert